The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2018 | CAR T-cell therapy for lung cancer?
CAR T-cells are an exciting therapeutic area, which although promising are still in the early stages of development for solid malignancies. Speaking from the British Thoracic Oncology Group (BTOG) Annual Conference 2018, held in Dublin, Ireland, Alastair Greystoke, PhD, of the University of Newcastle & Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK, discusses this area. Dr Greystoke highlights the need to improve targeting, giving examples of target antigens currently being investigated for lung cancer.
